Kt. Yeo et al., VASCULAR-PERMEABILITY FACTOR (VASCULAR ENDOTHELIAL GROWTH-FACTOR) IN GUINEA-PIG AND HUMAN TUMOR AND INFLAMMATORY EFFUSIONS, Cancer research, 53(12), 1993, pp. 2912-2918
Vascular permeability factor (VPF), also known as vascular endothelial
growth factor, is a dimeric M(r) 34,000-42,000 glycoprotein that poss
esses potent vascular permeability-enhancing and endothelial cell-spec
ific mitogenic activities. It is synthesized by many rodent and human
tumor cells and also by some normal cells. Recently we developed a sen
sitive and specific time-resolved immunofluorometric assay for quantif
ying VPF in biological fluids. We here report findings with this assay
in guinea pigs and patients with both malignant and nonmalignant effu
sions. Line 1 and line 10 tumor cells were injected into the peritonea
l cavities of syngeneic strain 2 guinea pigs, and ascitic fluid, plasm
a. and urine were collected at various intervals. Within 2 to 4 days,
we observed a time-dependent, parallel increase in VPF, ascitic fluid
volume, and tumor cell numbers in animals bearing either tumor line; i
n contrast, VPF was not detected in plasma or urine, even in animals w
ith extensive tumor burdens. However, low levels of VPF were detected
in the inflammatory ascites induced by i.p. oil injection. In human st
udies, high levels of VPF (> 10 pM) were measured in 21 of 32 effusion
s with cytology-documented malignant cells and in only seven of 35 eff
usions without cytological evidence of malignancy. Thus, VPF levels in
human effusions provided a diagnostic test for malignancy with a sens
itivity of 66% and a specificity of 80% (perhaps as high as 97% in tha
t six of the seven cytology-negative patients with VPF levels > 10 pM
had cancer as determined by other criteria). As in the animal tumor mo
dels, VPF was not detected in serum or urine obtained from patients wi
th or without malignant ascites. Many nonmalignant effusions contained
measurable VPF but, on average, in significantly smaller amounts than
were found in malignant effusions. VPF levels in such fluids correlat
ed strongly (rho = 0.59, P < 0.001) with monocyte and macrophage conte
nt. Taken together, these data relate ascitic fluid accumulation to VP
F concentration in a well-defined animal tumor system and demonstrate,
for the first time, the presence of VPF in human malignant effusions.
It is likely that VPF expression by tumor and mononuclear cells contr
ibutes to the plasma exudation and fluid accumulation associated with
malignant and certain inflammatory effusions. The VPF assay may prove
useful for cancer diagnosis as a supplement to cytology, especially in
tumors that grow in the pleural lining but not as a suspension in the
effusions that they induce.